Introduction
============

Infliximab, a chimeric monoclonal antibody to TNF-α, showed efficacy for ankylosing spondylitis (AS) in a randomised, placebo-controlled trial in which 61.2% of the patients were responders at 24 weeks \[[@B1]\]. Although methotrexate (MTX) is often used for patients with predominantly peripheral AS and those with psoriatic arthritis, the few attempts to treat predominantly axial disease were disappointing. Haibel *et al*. \[[@B2]\] studied 20 patients with AS who received MTX 15 to 20 mg/week subcutaneously and found no difference in Assessment in Ankylosing Spondylitis 20% improvement criteria (ASAS 20) scores before and 16 weeks after treatment. Until now, MTX has been evaluated in only three small, randomised, controlled trials \[[@B3]-[@B5]\], and a Cochrane review \[[@B6]\] concluded that there was insufficient evidence to support the use of MTX for AS with predominantly axial symptoms.

Data comparing infliximab with and without MTX treatment in AS are sparse and conflicting. Pérez-Guijo *et al*. \[[@B7]\] found a greater reduction in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores with infliximab + MTX treatment than with infliximab alone, whereas Breban *et al*. \[[@B8]\] found no statistically significant difference between patients who did or did not receive MTX in a subset of AS patients receiving treatment with infliximab by an on-demand strategy. However, in the latter study, patients receiving MTX showed a better response and fewer reactions to infusions than did patients not receiving MTX, although the results were not statistically significant \[[@B8]\]. Currently, regarding TNF-α antagonist therapy for patients with AS or psoriatic arthritis, the French Society for Rheumatology recommendations suggest that there is insufficient evidence for concomitant disease-modifying antirheumatic drugs improving the effectiveness of TNF-α antagonist therapy \[[@B9]\].

To date, no study has used infliximab exposure as an end point to compare treatment with the combination of infliximab and MTX with infliximab alone in AS with predominantly axial symptoms. Indeed, if such a combination increases exposure to infliximab, it should improve response and may be recommended in clinical practice. In the present study, we compared the individual exposure to infliximab of AS patients with predominantly axial symptoms receiving infliximab alone or infliximab and MTX combined.

Materials and methods
=====================

Patients and study protocol
---------------------------

From January 2008 to April 2009, AS patients with predominantly axial symptoms were recruited to participate in this two-centre, open-label, prospective, randomised study comparing treatment with infliximab alone and infliximab with MTX. All patients fulfilled the New York revised criteria for AS \[[@B10]\]. Infliximab was given intravenously (5 mg/kg) at weeks 0, 2, 6, 12 and 18 in accordance with our guidelines \[[@B9]\]. MTX 10 mg was given orally every week. After patients were randomised to a treatment group, a total of 12 visits were scheduled at each infliximab infusion and between infusions at 1, 3, 4, 5, 8, 10 and 14 weeks. Blood samples were collected before and two hours after the end of each infusion and at each visit. We estimated that we needed about 30 patients to compare infliximab exposure between the two treatment groups. The study protocol was in compliance with the Declaration of Helsinki, approved by the ethic committee of Tours University Hospital and registered (ClinicalTrials.gov ID: NCT00507403). All patients gave their informed consent to participate in the study.

Clinical measurements
---------------------

At each visit, patients were asked to complete a BASDAI questionnaire and were classified as responders if their BASDAI score (on a 10-point scale) at week 18 was two points lower than at baseline \[[@B9],[@B11]\]. Treatment response was also assessed according to the Assessment in Ankylosing Spondylitis 20% improvement criteria (ASAS 20).

Serum infliximab and antibodies toward infliximab concentrations
----------------------------------------------------------------

Analyses of serum infliximab and antibody toward infliximab (ATI) concentrations were centralised in Tours University Hospital. Infliximab serum concentration was measured in samples by using ELISA as described previously \[[@B12]\]. Serum concentration of ATI was measured by using a double-antigen ELISA on the basis of capture by infliximab-coated microplates and detection by peroxidase-conjugated infliximab. This assay was standardised by the use of a mouse monoclonal antibody against human immunoglobulin G. The positive threshold of detection was 0.07 mg/L. Because of the interference of circulating infliximab, only sera with infliximab concentrations \< 2 mg/L were tested.

Statistical analysis
--------------------

Individual exposure to infliximab was estimated by the cumulative area under the concentration versus time curve between baseline and week 18 (AUC~0-18~) by population pharmacokinetics modelling. The best description of infliximab concentrations was obtained by use of a two-compartment model with first-order distribution and elimination constants. Characteristics at baseline and the proportion of responders in each group were compared by using nonparametric tests. The results are presented in Table [1](#T1){ref-type="table"} as medians \[range\] unless otherwise stated. Statistical analysis involved the use of R 2.7.2 software \[[@B13]\].

###### 

Baseline characteristics of 26 patients with ankylosing spondylitis and predominantly axial symptoms randomised to receive infliximab or infliximab + methotrexate^a^

  -----------------------------------------------------------------------------------------------
  Characteristics                          Infliximab\           Infliximab + MTX\     *P*value
                                           (*n*= 12)             (*n*= 14)             
  ---------------------------------------- --------------------- --------------------- ----------
  Sex, men/women (*n*/%)                   9/3 (75/25)           11/3 (79/21)          0.8

  Median age, years                        42.5 \[27 to 59\]     45.5 \[29 to 55\]     0.3

  Median disease duration, years           4.0 \[0 to 28\]       4.5 \[1 to 19\]       0.9

  Human leukocyte antigen B27^+^, *n*(%)   9 (75)                10 (71)               0.8

  NSAIDs, *n*(%)                           8 (67)                12 (86)               0.5

  Previous TNF-α, *n*(%)                   2 (17)                2 (14)                1.0

  Median BASDAI score                      5.8 \[3.9 to 8.4\]    7.0 \[5.0 to 8.2\]    0.2

  Median C-reactive protein, mg/L          3.6 \[0.5 to 18.0\]   2.7 \[0.5 to 31.2\]   0.5
  -----------------------------------------------------------------------------------------------

^a^MTX: methotrexate; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; NSAIDs: nonsteroidal anti-inflammatory drugs. Results are given as medians \[range\] unless otherwise indicated.

Results
=======

We included 26 patients: 12 in the infliximab-only group and 14 in the infliximab + MTX group. The patients\' characteristics at baseline are given in Table [1](#T1){ref-type="table"}. A total of 507 samples were available for measurement of serum infliximab concentrations. Individual AUC~0-18~results for infliximab are shown in Figure [1](#F1){ref-type="fig"}. The two treatment groups did not differ in terms of AUC~0-18~results. The median AUC~0-18~value was 165,502 mg/hour/L \[50,569 to 203,782\] for the infliximab-only group and 164,222 mg/hour/L \[102,165 to 295,858\] for the infliximab + MTX group. Likewise, MTX had no effect on estimated pharmacokinetics parameters (data not shown). Positivity for ATI was detected in only one patient, a 43-year-old woman in the infliximab-only group who was negative for human leukocyte antigen B27. At weeks 4, 5 and 6, her infliximab concentrations were \< 1 mg/L and ATIs were detected at weeks 12 and 18. Her exposure to infliximab was low (AUC~0-18~= 50,569 mg/hour/L), and the infliximab elimination clearance was twice that of ATI-negative patients (data not shown).

![**Area under the concentration curve versus the time curve for serum infliximab concentration between baseline and week 18 (AUC~0-18~) for patients with ankylosing spondylitis who had predominantly axial symptoms and were receiving infliximab or infliximab + methotrexate (MTX) treatment**. The patient with anti-infliximab antibodies is shown as an open circle.](ar3350-1){#F1}

The two groups did not differ with regard to clinical activity or inflammation. Responses between the two groups were similar at week 18 (Additional file [1](#S1){ref-type="supplementary-material"}). Responders displayed a rapid decrease in BASDAI score compared with nonresponders, with a statistically significant difference observed at week 6 and thereafter (Additional file [2](#S2){ref-type="supplementary-material"}). The proportions of previous anti-TNF-α and current NSAIDs were similar in both responders and nonresponders.

Discussion
==========

We did not observe any influence of MTX on infliximab exposure in AS patients with predominantly axial symptoms. Our study is the first to answer the question whether MTX may affect infliximab pharmacokinetics in AS with predominantly axial symptoms. Previously, Krisiek *et al*. \[[@B14]\] analysed blood samples from AS patients receiving treatment with infliximab by an on-demand strategy with or without MTX. In their *post hoc*analysis involving 34 patients receiving MTX and 42 patients not receiving MTX, infliximab concentrations were measured at weeks 2 and 6 after treatment. The authors found no significant difference in infliximab levels between the two groups. Our results are in agreement with these previously published results and provide a precise estimation of the drug exposure with repeated and prolonged measurement of infliximab.

We found no difference between treatment groups with regard to change in BASDAI scores or ASAS 20 criteria, findings which are in agreement with results from previous controlled trials \[[@B3]-[@B5]\]. Although clinical outcome was not our objective, our results do not argue for a clinical benefit of adding MTX to infliximab treatment (5 mg/kg/infusion) for AS with predominantly axial symptoms. Patients who were responders at week 18 showed a rapid decrease in BASDAI scores, which suggests that an early decrease in BASDAI score may predict a response later on. By contrast, a patient who has not responded at 6 weeks after initiation seems likely to be a primary nonresponder.

The MTX dosage we used, 10 mg/week orally, was in agreement with the recommendation by an expert opinion of a broad international panel of rheumatologists \[[@B15]\]. A subcutaneous route or higher dosage than 10 mg/week would not likely have changed our results, because a previous study found no clinical response in patients with AS receiving MTX 15 to 20 mg/week subcutaneously \[[@B2]\].

We observed an important variability in infliximab exposure in both groups of patients. This variability has been reported in previous studies in which trough concentration was measured \[[@B14],[@B16]\]. Our study provides a more precise characterisation of this variability and confirms that exposure to treatment differs considerably among individuals.

We found that one patient was positive for ATI. Of note, this patient did not receive MTX, and this finding raises the question of the hypothetical role of immunosuppressive agents in preventing immunisation as reported in rheumatoid arthritis (RA) and Crohn\'s disease \[[@B17]-[@B19]\]. Because of the small number of participants and the relatively short duration of the study, no conclusion can be drawn regarding the potential role of MTX in reducing immunogenicity in AS.

Our results differ from those of Maini *et al*. \[[@B17]\], who found that MTX increased infliximab concentrations in RA. In RA, disease activity at baseline was found to be negatively associated with infliximab trough concentration at 6 weeks after initiation of treatment \[[@B20],[@B21]\]. This phenomenon may be explained by targeted mediated-drug disposition and high levels of TNF-α (which corresponds to antigenic burden) binding infliximab, which influence its pharmacokinetics. MTX is effective as monotherapy in patients with RA by decreasing TNF-α levels, which in turn increase infliximab concentrations \[[@B17]\]. That MTX did not improve infliximab exposure in our study patients with AS who had predominantly axial symptoms may reflect the fact that TNF-α antigenic burden is lower in AS than in RA.

Conclusion
==========

MTX seems to have no significant effect on infliximab pharmacokinetics in AS with predominantly axial symptoms. These results do not argue for adding MTX to infliximab therapy in this condition.
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###### Additional file 1

**Figure S1**. Percentage of responders according to Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ( \> 2-point reduction between baseline and week 18) and Assessment in Ankylosing Spondylitis 20% improvement criteria (ASAS 20) for patients with ankylosing spondylitis who had predominantly axial symptoms and were receiving infliximab or infliximab + methotrexate (MTX) treatment.
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###### Additional file 2

**Figure S2**. Changes in BASDAI scores for treatment responders (filled circles; *n*= 12) and nonresponders (open circles; *n*= 14) receiving infliximab alone or infliximab + methotrexate treatment. ^†^*P*\< 0.05. ^‡^*P*\< 0.01.
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